Ubs Group Ag Kinnate Biopharma Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$2.24 - $2.66 $9,571 - $11,366	-4,273 Reduced 83.93%	818 $2,000
Q4 2023 Feb 09, 2024	BUY	$1.07 - $2.5 $5,447 - $12,727	5,091 New	5,091 $12,000
Q4 2021 Feb 14, 2022	SELL	$16.5 - $25.48 $12,045 - $18,600	-730 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $8,513 - $11,887	478 Added 189.68%	730 $17,000
Q2 2021 Aug 13, 2021	SELL	$22.19 - $31.55 $11,893 - $16,910	-536 Reduced 68.02%	252 $6,000
Q1 2021 May 12, 2021	SELL	$26.99 - $40.0 $1.06 Million - $1.57 Million	-39,165 Reduced 98.03%	788 $25,000
Q4 2020 Feb 11, 2021	BUY	$36.35 - $45.25 $1.45 Million - $1.81 Million	39,953 New	39,953 $1.59 Million

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.